First subject receives DR10624 for the treatment of obesity and hypertriglyceridemia
Zhejiang Doer Biologics, a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and...
top of page
Browse by category
Search
Browse by tag
bottom of page